A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Apalutamide (Primary) ; Antiandrogens
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
Most Recent Events
- 14 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2022 Evaluation time of primary endpoints changed from 3.5 years to 4.9 years
- 15 Aug 2022 Planned End Date changed from 16 Jan 2026 to 5 Jun 2026.